This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read MaxCyte’s 8K filing here.
About MaxCyte
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Read More
- Five stocks we like better than MaxCyte
- How to Calculate Return on Investment (ROI)
- How to Master Trading Discipline: Overcome Emotional Challenges
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Does China Investigation Change NVIDIA’s Outlook; Yes, No, Maybe?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?
